Phase 1 N=35 A Study to Learn About Study Medicine Called PF-07261271 in Healthy People
Healthy
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs): SAD Cohort — 4; 1; 1; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=57 A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002)
Ulcerative Colitis
Primary: Number of Participants Who Experienced an Adverse Event (AE) — 7; 10; 18; 10 Participants
Phase 1 N=28 A Study to Compare How the Study Medicine (PF-07923568) is Processed in Participants With Different Levels of Loss of Liver Function to Healthy Participants.
Liver Diseases · Hepatic Impairment
Primary: Plasma Maximum Concentration (Cmax) of Sisunatovir Following Administration of a Single Oral Dose — 81.25; 68.52; 73.85; 127.8 Nanograms/milliliter (ng/mL)
Phase 1 N=7 Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus
Cutaneous Lupus
Primary: Change in Percentage of UVB-induced Apoptotic Epidermal Cells — 20.06; 3.03; -17.03 percentage of epidermal cells
Phase 1 N=46 A Study of the Effect of Food on Selpercatinib (LY3527723) in Healthy Participants
Healthy
Primary: Pharmacokinetics(PK): Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Selpercatinib — 23400; 22500 nanogram * hour per…
Phase 1 N=42 A Study to Learn How the Body Processes Spironolactone and Hydrochlorothiazide Film Coated Tablets Manufactured at Two Sites: Viatris and Neolpharma
Healthy Participants
Primary: Maximum Plasma Concentration (Cmax) of Spironolactone and Hydrochlorothiazide Following a Single Oral Dose of Spironolactone/Hydrochlorothiazide 25/25 mg Film Coated…
Phase 1 N=38 Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects
Healthy Subjects
Primary: QTc Effect of Single Subcutaneous (SC) Injections of Motixafortide (BL-8040) 1.25 mg/kg and 2 mg/kg — -0.6; 1.1; -3.0; -1.1 ms
Phase 1 N=51 First in Human Study to Assess Safety of VIS649 in Healthy Subjects
Immunoglobulin A Nephropathy · IgAN - IgA Nephropathy · IgA Nephropathy
Primary: Overall Summary of Treatment Emergent Adverse Events — 8; 3; 7; 7 Event
Phase 1 N=20 A Study in Healthy Men to Test Whether BI 1358894 Reduces Druginduced Panic Symptoms
Healthy
Primary: Maximum Change From Baseline in Panic Symptom Scale (PSS) Sum Intensity Score — 22.639; 29.944 Score on a scale
Phase 1 N=86 PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma
Multiple Myeloma
Primary: Part 1: Number of Participants With Drug Limiting Toxicities (DLTs) Graded According to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE)…
Phase 1 N=77 Study of the Gut Hormone Analogue Y14 in Adult Subjects
Diabetes Mellitus · Obesity
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) (Safety and Tolerability) — 2; 1; 1; 3 Participants
Phase 1 N=12 Exploratory Study to Assess Delivery of LMN-201 Components Via Enteric Capsules in the Gut of Individuals With Ostomies
C. Diff. Infections
Primary: Number of Participants With Presence of Capsules and/or Transit Markers in Ostomy Fluid by Visual Observation — 0; 0; 0; 0 Participants
Phase 1 N=16 A Study of the Effects of Pirtobrutinib (LOXO-305) on Repaglinide (CYP2C8 Substrate) in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Repaglinide — 9.59; 22.2 hour*nanogram per…
Phase 1 N=42 A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Selpercatinib — 176; 174; 180 nanograms per milliliter (ng/mL)
Phase 1 N=224 A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Selpercatinib — 1520; 1350 nanograms per milliliter (ng/mL)